
Opinion|Videos|May 27, 2025
Identifying Nonadherence in Patients With Hyperlipidemia
Panelists discuss how clinical teams can identify and address nonadherence to statin and nonstatin therapies by leveraging electronic health record (EHR) systems for adherence monitoring and optimizing patient outcomes.
Advertisement
Episodes in this series

Nonadherence to Lipid-Lowering Therapies: Identification and Management Strategies
Key Approaches for Identifying Nonadherence
- Direct assessment methods:
- Medication possession ratio and proportion of days covered calculations
- Pharmacy refill data monitoring
- Prescription claims database analysis
- Serum drug level measurements when available
- Indirect assessment methods:
- Structured patient interviews using validated questionnaires (e.g., Morisky Medication Adherence Scale)
- Patient self-reporting with nonjudgmental questioning
- Clinical response evaluation (monitoring lipid levels for expected reductions)
Effective Interventions for Improving Adherence
- Simplification of regimens: Once-daily dosing, fixed-dose combinations, and polypills
- Patient education: Personalized counseling about cardiovascular risk and medication benefits
- Behavioral interventions: Reminder systems, medication organizers, and habit formation
- Shared decision-making: Involving patients in treatment decisions and addressing concerns
- Team-based care: Leveraging pharmacists, nurses, and care managers for adherence support
- Cost-reduction strategies: Prescribing generics, assistance programs, and formulary optimization
Electronic Medical Record - Based Strategies for Adherence Monitoring
- Implement automated alerts for missed refills or appointments
- Create dashboards displaying medication adherence metrics
- Design clinician-friendly adherence assessment tools within workflow
- Integrate prescription claims data with clinical systems when possible
- Develop standardized documentation templates for adherence discussions
- Utilize patient portals for education and medication reminders
- Configure clinical decision support tools to identify high-risk patients
Implementation Recommendations
- Establish systematic screening for nonadherence during routine visits
- Use multifaceted interventions tailored to specific adherence barriers
- Apply quality improvement methodology to local adherence initiatives
- Monitor program effectiveness with clearly defined metrics
- Consider adherence monitoring as an essential component of lipid management
Advertisement
Related to this article

Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.

This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.

Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.

Pharmacy professionals can leverage LinkedIn to build a professional brand, expand meaningful connections, share expertise, and create opportunities for career growth.

An Italian pharmacy student offers an inside look at pharmacy education in Italy, from admission and coursework to oral exams and professional training.
Advertisement
Advertisement
Trending on Pharmacy Times
1
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
2
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
3
Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?
4
Pharmacists Positioned as Key Educators as Monoclonal Antibodies Emerge as COVID-19 Immunization Option
5




